Skip to content

BHIVA: Starting ART earlier has cost implications, public health benefits, says HPA

Combining rifampicin with increased doses of lopinavir/ritonavir tablets leads to dangerous increases in liver enzymes

Death rate in Malawi falls by up to 35% due to free HIV treatment

Does tenofovir increase the risk of efavirenz-associated liver side-effects?

Nearly all patients with NNRTI resistance could benefit from etravirine, UK analysis shows

BHIVA: Many patients and clinicians still need educating about the benefits of treatment

Insulin resistance may predict risk of cardiovascular disease in HIV

Planned interruption of highly active antiretroviral therapy does not select drug resistance mutations in HIV-1-infected children

African-Americans with HIV have higher risk of aggressive kidney disease